Volume 9 Supplement 2

Controversies in breast cancer

Short communications

Edited by William R Miller, Lesley J Fallowfield, Mitch Dowsett, Richard J Santen, James N Ingle

The Symposium and supplement were supported by unrestricted educational grants from AstraZeneca, Novartis, Pfizer and Roche

Controversies in Breast Cancer 2007.

Edinburgh, UK

3-4 September 2007

Previous Page Page 1 of 2 Next Page
  1. Review

    HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors

    Overexpression of the human epidermal growth factor receptor (HER)-2 oncogenic receptor tyrosine kinase, which occurs in 25% of breast cancers, portends poor clinical outcome and consequently represents an att...

    Neil Spector, Wenle Xia, Iman El-Hariry, Yossi Yarden and Sarah Bacus

    Breast Cancer Research 2007 9(Suppl 2):205

    Published on: 2 March 2007

Previous Page Page 1 of 2 Next Page